{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:32:18Z","timestamp":1785465138929,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejso.2025.110080","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:27:16Z","timestamp":1745029636000},"page":"110080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Mitomycin versus Oxaliplatin debate on HIPEC in colorectal cancers - An updated systematic review and Meta-analysis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-0006","authenticated-orcid":false,"given":"Mufaddal","family":"Kazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Ajith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6898","authenticated-orcid":false,"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ejso.2025.110080_bib1","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110080_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110080_bib3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2025.110080_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study","volume":"21","author":"Go\u00e9r\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110080_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2025.110080_bib6","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.21037\/jgo-2020-05","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7","volume":"12","author":"Cashin","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2025.110080_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial","volume":"158","author":"Arjona-S\u00e1nchez","year":"2023","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.ejso.2025.110080_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1245\/s10434-023-14368-5","article-title":"2022 peritoneal surface oncology group international consensus on HIPEC regimens for peritoneal malignancies: colorectal cancer","volume":"31","author":"H\u00fcbner","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110080_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae017","article-title":"Hyperthermic intraperitoneal chemotherapy in colorectal cancer","volume":"8","author":"Fisher","year":"2024","journal-title":"BJS Open"},{"issue":"10","key":"10.1016\/j.ejso.2025.110080_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s00384-020-03702-y","article-title":"Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies","volume":"35","author":"Zhang","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.ejso.2025.110080_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"2","key":"10.1016\/j.ejso.2025.110080_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.110080_bib13","author":"Wells"},{"key":"10.1016\/j.ejso.2025.110080_bib14","series-title":"McMaster university and evidence prime","article-title":"GRADEpro guideline development tool [software]","author":"Gradepro","year":"2024"},{"key":"10.1016\/j.ejso.2025.110080_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Software"},{"issue":"3","key":"10.1016\/j.ejso.2025.110080_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.ejso.2025.110080_bib17","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-019-07935-2","article-title":"Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-based HIPEC: a comparative study using the peritoneal surface disease severity score (psdss)","volume":"27","author":"Baratti","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110080_bib18","article-title":"Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC","volume":"44","author":"Eden","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110080_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1245\/s10434-006-9167-9","article-title":"Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis","volume":"14","author":"Elias","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110080_bib20","article-title":"Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"34","author":"Ghc","year":"2018","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"issue":"6","key":"10.1016\/j.ejso.2025.110080_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jso.23228","article-title":"Treatment\u2010related morbidity and toxicity of CRS and oxaliplatin\u2010based HIPEC compared to a mitomycin and doxorubicin\u2010based HIPEC protocol in patients with peritoneal carcinomatosis: a matched\u2010pair analysis","volume":"107","author":"Glockzin","year":"2012","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110080_bib22","first-page":"525","article-title":"Oxaliplatin in the treatment of colorectal cancer","author":"Jacobson","year":"2003","journal-title":"Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2025.110080_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamcollsurg.2017.12.027","article-title":"A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors","volume":"226","author":"Levine","year":"2018","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.ejso.2025.110080_bib24","article-title":"Comparison of efficacy of hyperthermic intraperitoneal chemotherapeutics mitomycin C versus oxaliplatin in experimental colorectal peritoneal metastasis model","volume":"8","author":"Mano\u011flu","year":"2024","journal-title":"J Basic Clin Health Sci [Internet]"},{"issue":"5","key":"10.1016\/j.ejso.2025.110080_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/02656736.2017.1345014","article-title":"Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"34","author":"Tan","year":"2018","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"issue":"1","key":"10.1016\/j.ejso.2025.110080_bib26","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jss.2012.01.015","article-title":"A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C","volume":"179","author":"Votanopoulos","year":"2013","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejso.2025.110080_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.critrevonc.2019.06.014","article-title":"Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer","volume":"142","author":"Wisselink","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110080_bib28","first-page":"266","article-title":"Hyperthermic intraperitoneal chemotherapy with mitomycin C versus oxaliplatin after cytoreductive surgery for the treatment of peritoneal metastases of colorectal cancer origin","volume":"117","author":"Papageorgopoulou","year":"1990","journal-title":"Chir Buchar Rom"},{"issue":"1","key":"10.1016\/j.ejso.2025.110080_bib29","article-title":"Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis","volume":"43","author":"Leung","year":"2017","journal-title":"Eur J Surg Oncol [Internet]"},{"issue":"10","key":"10.1016\/j.ejso.2025.110080_bib30","article-title":"Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study","volume":"46","author":"Bakkers","year":"2020","journal-title":"Eur J Surg Oncol [Internet]"},{"issue":"2","key":"10.1016\/j.ejso.2025.110080_bib31","article-title":"Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study","volume":"64","author":"Benzaquen","year":"2021","journal-title":"Can J Surg J Can Chir"},{"issue":"12","key":"10.1016\/j.ejso.2025.110080_bib32","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1245\/s10434-022-12221-9","article-title":"Peritoneal metastases of colorectal origin treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy: the efficiency of mitomycin C","volume":"29","author":"Delhorme","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110080_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/bjs5.50250","article-title":"Effect of intraperitoneal chemotherapy concentration on morbidity and survival","volume":"4","author":"Elekonawo","year":"2020","journal-title":"BJS Open"},{"issue":"6","key":"10.1016\/j.ejso.2025.110080_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/jso.23546","article-title":"The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study","volume":"109","author":"Hompes","year":"2014","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110080_bib35","first-page":"E342","article-title":"A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies","volume":"65","author":"Nassabein","year":"2022","journal-title":"Can J Surg J Can Chir"},{"issue":"7","key":"10.1016\/j.ejso.2025.110080_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jso.23728","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Prada-Villaverde","year":"2014","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110080_bib37","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C","volume":"106","author":"Rouers","year":"2006","journal-title":"Acta Chir Belg"},{"issue":"2","key":"10.1016\/j.ejso.2025.110080_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107865","article-title":"Peritoneal recurrence following cytoreductive surgery combined with oxaliplatin vs. mitomicin C- based heated intraperitoneal chemotherapy for colorectal peritoneal metastases","volume":"50","author":"Sanchez","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.110080_bib39","article-title":"Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis","volume":"26","author":"Spiliotis","year":"2021","journal-title":"J BUON Off J Balk Union Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2025.110080_bib40","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/jso.25920","article-title":"Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer","volume":"121","author":"Woeste","year":"2020","journal-title":"J Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110080_bib41","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00384-020-03702-y","article-title":"Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies","volume":"35","author":"Zhang","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ejso.2025.110080_bib42","article-title":"Oncological outcomes from cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal cancer peritoneal metastases","author":"Tinsley","year":"2024","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejso.2025.110080_bib43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-022-09572-7","article-title":"GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases","volume":"22","author":"Pereira","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2025.110080_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294018","article-title":"Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol","volume":"19","author":"Ghanipour","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2025.110080_bib45","unstructured":"Study Details | ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis | ClinicalTrials.gov [Internet]. [cited 2024 Jul 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01815359?cond=Colorectal%20Cancer&intr=HIPEC&page=4&rank=35."},{"key":"10.1016\/j.ejso.2025.110080_bib46","unstructured":"Study Details | Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis | ClinicalTrials.gov [Internet]. [cited 2024 Jul 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03073694?cond=Colorectal%20Cancer&intr=HIPEC&page=5&rank=45."},{"key":"10.1016\/j.ejso.2025.110080_bib47","unstructured":"Study Details | HIPEC Using High Intra-abdominal Pressure | ClinicalTrials.gov [Internet]. [cited 2024 Jul 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02949791?cond=Colorectal%20Cancer&intr=HIPEC&rank=10."}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:39:29Z","timestamp":1755495569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325005086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0748798325005086"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110080","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Mitomycin versus Oxaliplatin debate on HIPEC in colorectal cancers - An updated systematic review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110080"}}